Skip to main content
Celgene reports on interim data for myeloma candidate iberdomide

Celgene announced interim results from a Phase I/II study for its investigational therapy iberdomide, or CC-220, combined with dexamethasone, in patients with relapsed/refractory multiple myeloma, which was found to be safe and was able to control the disease in almost 90% of trial participants. The preliminary data were unveiled during a presentation at the 2019 annual meeting of the American Society of Clinical Oncology.

Full Story: